Gene:
FANCL
Fanconi anemia, complementation group L

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB has no annotated drug labels with pharmacogenomic information for this . If you know of a drug label with PGx, send us a message.

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

Overview

Alternate Names:  PHF9
Alternate Symbols:  FAAP43; FLJ10335; Pog
PharmGKB Accession Id: PA134887656

Details

Cytogenetic Location: chr2 : p16.1 - p16.1
GP mRNA Boundary: chr2 : 58386378 - 58468515
GP Gene Boundary: chr2 : 58383378 - 58478515
Strand: minus

Visualization

UCSC has a Genome Browser that you can use to view PharmGKB annotations for this gene in context with many other sources of information.

View on UCSC Browser
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.
No related genes are available

Curated Information ?

Evidence Drug Class
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
antineoplastic agents

Curated Information ?

Evidence Disease
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Breast Neoplasms

Publications related to FANCL: 1

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Exome sequencing reveals frequent deleterious germline variants in cancer susceptibility genes in women with invasive breast cancer undergoing neoadjuvant chemotherapy. Breast cancer research and treatment. 2015. Ellingson Marissa S, et al. PubMed

LinkOuts

NCBI Gene:
55120
OMIM:
608111
RefSeq RNA:
NM_001114636
NM_018062
RefSeq Protein:
NP_001108108
NP_060532
RefSeq DNA:
NG_007418
NT_022184
UniProtKB:
FANCL_HUMAN (Q9NW38)
Ensembl:
ENSG00000115392
GeneCard:
FANCL
ALFRED:
LO028565A
HuGE:
FANCL
Comparative Toxicogenomics Database:
55120
ModBase:
Q9NW38
HumanCyc Gene:
HS12844
HGNC:
20748

Common Searches